Changjun Bao
Overview
Explore the profile of Changjun Bao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
1521
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huo X, Cui L, Zhu L, Zhang J, Fan H, Yi Y, et al.
J Infect Dev Ctries
. 2025 Jan;
18(12.1):S214-S226.
PMID: 39863937
Introduction: China implemented a dynamic zero-COVID strategy to curb viral transmission in response to the coronavirus disease 2019 (COVID-19) pandemic. This strategy was designed to inhibit mutation of severe acute...
2.
Zhang S, Kong X, Zhen Q, Wei Y, Shi C, Ding S, et al.
J Med Virol
. 2025 Jan;
97(1):e70161.
PMID: 39780477
As the COVID-19 pandemic continues, increasingly complex vaccination and infection histories have made it urgent to investigate the antibody dynamics in populations with hybrid immunity. This study aimed to explore...
3.
Peng H, Wang Y, Wei S, Kang W, Zhang X, Cheng X, et al.
Front Public Health
. 2024 Dec;
12:1476748.
PMID: 39697280
Objective: This study aimed to analyze the trends in Hepatitis A incidence associated with age, period, and birth cohorts from 2007 to 2021 in Jiangsu Province, China, and projects the...
4.
Wang X, Yu H, Ma Y, Zhang P, Wang X, Liang J, et al.
mBio
. 2024 Dec;
16(2):e0236324.
PMID: 39679681
Following two human infections with the H10N3 avian influenza virus (AIV) in 2021 and 2022, a third case was discovered in Yunnan, China, in 2024, raising concerns about the potential...
5.
Zhang S, Wang Y, Xu G, Dong C, Tian H, Li C, et al.
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591114
Background: Previous SARS-CoV-2 infection provides some level of protection against reinfection. However, few studies have evaluated the neutralizing antibody (NAb) response after Delta variant infection and its ability to prevent...
6.
Dai Q, Bao C, Ju H, Li N, Wang S, Wen J, et al.
J Infect Dev Ctries
. 2024 Nov;
18(9.1):S92-S100.
PMID: 39499752
Introduction: This study aimed to assess COVID-19 re-infection rates among individuals previously infected between 2020 and November 2022, particularly during the first wave of high-intensity transmission, and to identify the...
7.
Simayi A, Chen Y, Chu J, Yu H, Zhang S, Bao C, et al.
Emerg Microbes Infect
. 2024 Oct;
13(1):2412619.
PMID: 39360715
Here, we regularly followed two SARS-CoV-2 infected cohorts to investigate the combined effects of neutralizing antibodies (NAbs) and B and T cell profiles during the convalescent period. Ten infected participants...
8.
Deng F, Dong Z, Qiu T, Xu K, Dai Q, Yu H, et al.
Virol J
. 2024 Sep;
21(1):226.
PMID: 39304902
Background: Respiratory infectious diseases have the highest incidence among infectious diseases worldwide. Currently, global monitoring of respiratory pathogens primarily focuses on influenza and coronaviruses. This study included influenza and other...
9.
Shi Y, Xu L, Jiang H, Cai Y, Bao C, Liu W
Front Public Health
. 2024 Aug;
12:1409004.
PMID: 39100958
Objective: This study aims to analyze the awareness of influenza prevention and control and the behavioral attitudes toward the work among parents and staff in schools in Taicang City and...
10.
Chu J, Dai Q, Dong C, Kong X, Tian H, Li C, et al.
Front Public Health
. 2024 Jun;
12:1364048.
PMID: 38873290
Background: It is important to figure out the immunity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reinfection to understand the response of humans to viruses. A serological survey for...